Relevant publications

MSIF’s 2023 application to the WHO Essential Medicines List

• Editorial: Towards equitable access to treatment for multiple sclerosis

The Lancet Neurology, 2023;22(3):189. doi:10.1016/S1474-4422(23)00041-8

• Proposal for inclusion of multiple sclerosis disease-modifying therapies (DMTs) on the complementary WHO Model Lists of Essential Medicines

Application to WHO EML, 2022

• Access For All: Adding MS DMTs to the WHO Essential Medicines List

ECTRIMS Podcast, Episode 12

• Editorial: Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation

Yamout BI, Viswanathan S, Laurson-Doube J and Sokhi D. Multiple Sclerosis Journal. doi.org/10.1177/13524585231205970

• Correspondence: WHO considers multiple sclerosis treatments essential

Laurson-Doube J et al. Lancet Neurology, 2024; 23(2); 140. doi.org/10.1016/S1474-4422(23)00505-7

MSIF’s 2019 application to the WHO Essential Medicines List

• Editorial: Essential medicines for patients with multiple sclerosis

The Lancet Neurology, 2019;18(12):1067. doi:10.1016/S1474-4422(19)30390-4

• Health-care disparities for people with multiple sclerosis

Laurson-Doube J, et al. The Lancet Neurology, 2020;19(3):207-208. doi:10.1016/S1474-4422(19)30486-7

• World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application

McDonell J, Costello K, Laurson-Doube J, et al. Multiple Sclerosis Journal. 2020;26(2):153-158. doi:10.1177/1352458519898340

Off-label MS DMTs

• Ethical use of off-label disease-modifying therapies for multiple sclerosis

Laurson-Doube J, Rijke N, Helme A, et al. Multiple Sclerosis Journal. 2021;27(9):1403-1410. doi:10.1177/13524585211030207

• Editorial: Fair and equitable treatment for multiple sclerosis in resource-poor regions: The need for off-label therapies and regional treatment guidelines

Pandit L. Multiple Sclerosis Journal. 2021; 27(9) doi:10.1177/1352458521102

• Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis

Piggott T, Nonino F, Baldin E, et al. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2021;7(4). doi:10.1177/20552173211051855

Barriers to accessing treatment

• Barriers to accessing multiple sclerosis disease-modifying therapies in the Middle East and North Africa region: A regional survey-based study

Zeineddine M, Al-Hajje A, Salameh P, et al. MSARD. doi:10.1016/j.msard.2023.104959

Barriers to diagnosis

• Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition

Solomon A, Marrie RA, Viswanathan S et al. Neurology. doi:10.1212/WNL.0000000000207481

• Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis

Kock-Henriksen N. Neurology. doi:10.1212/WNL.0000000000207530

The WHO intersectoral global action plan for epilepsy and other neurological disorders

• Intersectoral global action plan on epilepsy and other neurological disorders

World Health Organization

• Global synergistic actions to improve brain health for human development

Owolabi M, Leonardi M, Bassetti C et al. Nature Reviews Neurology. 2023;19:371–383. doi:10.1038/s41582-023-00808-z